| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:56 UTC |
|---|
| HMDB ID | HMDB0015297 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Cilostazol |
|---|
| Description | Cilostazol, also known as pletal, belongs to the class of organic compounds known as hydroquinolones. Hydroquinolones are compounds containing a hydrogenated quinoline bearing a ketone group. Cilostazol is an extremely weak basic (essentially neutral) compound (based on its pKa). Within humans, cilostazol participates in a number of enzymatic reactions. In particular, cilostazol can be converted into 4-hydroxycilostazol; which is mediated by the enzyme cytochrome P450 3A4. In addition, cilostazol can be converted into 4-cis-hydroxy cilostazol through its interaction with the enzymes cytochrome P450 2C19 and cytochrome P450 3A5. In humans, cilostazol is involved in cilostazol action pathway. A lactam that is 3,4-dihydroquinolin-2(1H)-one in which the hydrogen at position 6 is substituted by a 4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy group. |
|---|
| Structure | O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2 InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26) |
|---|
| Synonyms | | Value | Source |
|---|
| 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone | ChEBI | | 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone | ChEBI | | 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril | ChEBI | | 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one | ChEBI | | Cilostazolum | ChEBI | | Pletal | Kegg | | Cilostazole | HMDB |
|
|---|
| Chemical Formula | C20H27N5O2 |
|---|
| Average Molecular Weight | 369.4607 |
|---|
| Monoisotopic Molecular Weight | 369.216475133 |
|---|
| IUPAC Name | 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one |
|---|
| Traditional Name | cilostazol |
|---|
| CAS Registry Number | 73963-72-1 |
|---|
| SMILES | O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2 |
|---|
| InChI Identifier | InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26) |
|---|
| InChI Key | RRGUKTPIGVIEKM-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as hydroquinolones. Hydroquinolones are compounds containing a hydrogenated quinoline bearing a ketone group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Quinolines and derivatives |
|---|
| Sub Class | Quinolones and derivatives |
|---|
| Direct Parent | Hydroquinolones |
|---|
| Alternative Parents | |
|---|
| Substituents | - Tetrahydroquinolone
- Tetrahydroquinoline
- Alkyl aryl ether
- Benzenoid
- Azole
- Heteroaromatic compound
- Tetrazole
- Carboxamide group
- Lactam
- Secondary carboxylic acid amide
- Carboxylic acid derivative
- Ether
- Azacycle
- Hydrocarbon derivative
- Organic oxide
- Organic nitrogen compound
- Organopnictogen compound
- Carbonyl group
- Organic oxygen compound
- Organonitrogen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 160 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.032 g/L | Not Available | | LogP | 2.3 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.83 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.6053 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.93 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 38.3 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2654.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 259.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 193.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 174.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 242.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 554.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 634.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 130.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1321.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 489.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1514.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 408.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 404.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 303.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 200.8 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 83.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Cilostazol,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C21 | 3478.0 | Semi standard non polar | 33892256 | | Cilostazol,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C21 | 3295.5 | Standard non polar | 33892256 | | Cilostazol,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C21 | 4513.0 | Standard polar | 33892256 | | Cilostazol,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C21 | 3695.2 | Semi standard non polar | 33892256 | | Cilostazol,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C21 | 3516.0 | Standard non polar | 33892256 | | Cilostazol,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C21 | 4583.9 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Cilostazol GC-MS (Non-derivatized) - 70eV, Positive | splash10-0fal-8947000000-2a45c02fa8163a7e214e | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Cilostazol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Cilostazol LC-ESI-qTof , Positive-QTOF | splash10-0fc3-2900000000-aeed8cd6efbb3b93af8e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cilostazol , positive-QTOF | splash10-00dr-1698000000-05ddf5c1a046516bae11 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cilostazol , positive-QTOF | splash10-01t9-3920000000-86a7d65313952e9a8d3f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 10V, Positive-QTOF | splash10-00di-0129000000-f672b81f1eae1e02bf26 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 20V, Positive-QTOF | splash10-06za-7679000000-3558d68d922f50a245e5 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 40V, Positive-QTOF | splash10-001i-9600000000-a29f6d9a47bb72fd9433 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 10V, Negative-QTOF | splash10-014i-0529000000-1054f4f0e8e908b32dc8 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 20V, Negative-QTOF | splash10-03di-2913000000-c486550cc7475c61e6e3 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 40V, Negative-QTOF | splash10-01ox-5900000000-285688ae4185c24bab91 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 10V, Positive-QTOF | splash10-00di-0029000000-dcfc288c1d5ecab73a27 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 20V, Positive-QTOF | splash10-0089-9018000000-77173424302a7aea56fe | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 40V, Positive-QTOF | splash10-004i-0970000000-ddeea9f213a26978e589 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 10V, Negative-QTOF | splash10-014i-0109000000-55bee19f6f547c13b3b2 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 20V, Negative-QTOF | splash10-014i-0109000000-ad4dbc3d4880ce468bb5 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cilostazol 40V, Negative-QTOF | splash10-03di-1921000000-c6d1a1ca29c9d4653634 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|